Adjuvant Tebentafusp in High Risk Ocular Melanoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

November 11, 2024

Primary Completion Date

November 30, 2032

Study Completion Date

November 30, 2032

Conditions
Uveal Melanoma
Interventions
DRUG

Tebentafusp

Tebentafusp will be administered weekly i.v.

Trial Locations (9)

1200

RECRUITING

Cliniques Universitaires Saint-Luc, Brussels

2300

RECRUITING

Leiden University Medical Centre, Leiden

12200

RECRUITING

Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin

20246

RECRUITING

Universitaets Krankenhaus Eppendorf - Universitaetsklinikum Hamburg-Eppendorf KE - University Cancer Center, Hamburg

47003

RECRUITING

Hospital Clinico Universitario De Valladolid, Valladolid

75248

RECRUITING

Institut Curie - Hôpital de Paris, Paris

DE 69120

RECRUITING

Universitaetsklinikum Heidelberg - Frauenklinik / Hautklinik, Heidelberg

02 781

RECRUITING

Maria Sklodowska-Curie Memorial Cancer Centre - Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw

08908

RECRUITING

Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia), L'Hospitalet de Llobregat

Sponsors
All Listed Sponsors
collaborator

Northwell Health

OTHER

collaborator

Immunocore Ltd

INDUSTRY

lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK